RecruitingHealthy ParticipantsAtopic Dermatitis
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Eligible age
18–70 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Sponsor: Pfizer
You may qualify if…
- ✓ Part 1 only: Adult participants between 18 to 55 years of age, inclusive, at the time of signing the ICD
- ✓ Part 2 only: Adult participants, who at the time of screening, are between the ages of 18 and 70 years, inclusive.
- ✓ Part 1 only: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital sign assessments, temperature, 12-lead ECGs, laboratory tests
- ✓ BMI of 17.5 to 40 kg/m2; and a total body weight \>50 kg (110 lbs)
- ✓ Part 2 only: Must meet the following AD criteria:
- ✓ 1. Have a clinical diagnosis of chronic AD (also known as atopic eczema) for at least 1 year prior to Day 1 and have the diagnosis of AD confirmed by photographs (at screening) and diagnostic criteria for AD.
- ✓ 2. Either an inadequate response to treatment with standard of care treatments (excluding systemic immunosuppressant treatments) consistent with AD treatment guidelines (for at least 4 consecutive weeks within 6 to 12 months (depending on time since initial diagnosis) of the first dose of the study intervention. OR Have a documented reason why topical treatments are considered medically inappropriate within the last year.
- ✓ 3. Have moderate to severe AD (defined as having an affected BSA (captured as part of EASI) ≥10%, IGA ≥3, and EASI ≥12 at both the screening and baseline visits).
You may not qualify if…
- ✕ Have a history of systemic infection requiring hospitalization and parenteral antimicrobial therapy, any lymphoproliferative disorder, malignancies.
- ✕ Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological disorder.
- ✕ Have undergone significant trauma or major surgery within 1 month of the first dose of study intervention.
- ✕ Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by both of the following:
- ✕ 1. A positive QuantiFERON-TB Gold In-tube or equivalent test.
- ✕ 2. History of either untreated or inadequately treated latent or active TB infection, or current treatment for the same.
- ✕ Part 2 Only
- ✕ Currently have active forms of other inflammatory skin diseases
Where it's recruiting
Source: ClinicalTrials.gov · NCT06564389 · last updated 2026-07-22